[AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO)].
Geschäftsstelle der AUO, MeckEvidence, Seestraße 11, 17252 Schwarz, Deutschland. AUO@MeckEvidence.de
H
H
Rexer
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000556:secondary*; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D008137:Longitudinal Studies; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D008297:Male; D015995:Prevalence; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib